# VA Consolidation in Intermediate-Risk AML

> **NCT07672262** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 226 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Intermediate Risk Acute Myeloid Leukemia
- Consolidation Therapy

## Interventions

- **DRUG:** Venetoclax and Azacitidine
- **DRUG:** Cytarabine ± Anthracycline

## Key facts

- **NCT ID:** NCT07672262
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2030-06-01
- **Final completion:** 2030-06-01
- **Target enrollment:** 226 (ESTIMATED)
- **Last updated:** 2026-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07672262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07672262, "VA Consolidation in Intermediate-Risk AML". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07672262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*